As the omics landscape enters a new phase of maturity, Marc Claesen, CTO and Founder of Aspect Analytics, is helping shape how the industry transitions from data generation to data-driven insight and clinical impact.
Aspect Analytics operates at the intersection of spatial biology and advanced data science, delivering a scalable cloud platform for multi-omics analysis across biopharma and academia. The company’s core focus is enabling researchers to fully leverage increasingly complex datasets by integrating diverse modalities—including spatial transcriptomics, proteomics, mass spectrometry imaging, and histology—into a unified analytical environment.
What distinguishes Aspect Analytics is its commitment to true multi-omics integration with spatial context. Rather than analyzing cells in isolation, the platform enables interrogation of cellular neighborhoods, capturing how cells interact within their microenvironment. This approach reflects a broader industry shift: understanding biology not just at the molecular level, but within its spatial and functional context.
According to Claesen, the industry is now facing a critical inflection point. While data generation technologies have rapidly advanced, data analysis, accessibility, and reproducibility remain key bottlenecks. He highlights the urgent need for standardized workflows, robust quality control, and FAIR data principles to ensure that insights are not only generated, but also trusted and reusable.
A central theme for the next generation of omics is democratization. Claesen emphasizes that meaningful progress will require broader participation beyond computational specialists. Empowering biologists, clinicians, and pathologists to directly engage with data is essential to unlocking its full value. Platforms that facilitate collaboration across disciplines will be critical in this evolution.
On artificial intelligence, Claesen offers a balanced perspective. AI is a powerful enabler—capable of accelerating discovery and supporting data-driven clinical decision-making—but it is not without challenges. Understanding model limitations and mitigating risks such as “silent failures” will be essential as AI becomes more deeply embedded in omics workflows.
Looking ahead to the next phase of multi-omics, Claesen sees integration as the defining priority. The convergence of genomic, transcriptomic, proteomic, and spatial data is expected to drive the emergence of spatial molecular biomarkers, offering deeper insights into disease mechanisms and enabling more precise therapeutic strategies.
For biopharma, this shift presents a significant opportunity. Integrated multi-omics approaches can enhance target discovery, improve translational success, and refine patient stratification. However, realizing this potential will depend on strong collaboration across scientific, clinical, and technological domains.
As a Tech Partner at Next Gen Omics US 2026, Aspect Analytics is positioned to support this transformation—providing the tools, infrastructure, and expertise needed to turn complex omics data into actionable insight.
